The details of these notes and other loans and contingent liabilities are as follows:

									Fixed
								Conversion	Rate
Lender	1st-Issue	Principal		Duration		Interest		Price	EUR/USD
Price	Date	Amount		(Note)		Rate		(stated)	Conversion

Norwood Secured Loan	04/03/2009	E	1,500	(5	)	10% pa	$	None	N/A
Eardley Holding A.G. (1)	06/23/2006	E	138	(2	)	10% pa	$	0.10	N/A
Anglo Irish Bank S.A.(3)	10/21/2007	E	500	(2	)	10% pa	$	0.50	1.4090
Round Enterprises Ltd.	12/10/2007	E	1,500	(2	)	10% pa	$	0.50	1.4429
Round Enterprises Ltd.	01/22/2008	E	1,500	(2	)	10% pa	$	0.50	1.4629
Round Enterprises Ltd.	04/25/2008	E	2,000	(2	)	10% pa	$	0.50	1.5889
Round Enterprises Ltd.	06/30/2008	E	1,500	(2	)	10% pa	$	0.50	1.5380
Round Enterprises Ltd.	11/18/2008	E	1,200	(2	)	10% pa	$	0.50	1.2650
Round Enterprises Ltd.	02/09/2009	E	1,500	(2	)	10% pa	$	0.50	1.2940
Round Enterprises Ltd.	06/15/2009	E	5,500	(2,4	)	10% pa	$	0.80	1.4045
Eardley Holding A.G.	06/15/2009	E	100	(2,4	)	10% pa	$	0.80	1.4300
Von Meyenburg	08/03/2009	E	200	(2	)	10% pa	$	0.80	1.4400
Round Enterprises Ltd.	10/13/2009	E	2,000	(2	)	5% pa	$	0.25	1.4854
Round Enterprises Ltd.	12/18/2009	E	2,200	(2	)	5% pa	$	0.25	1.4338
Round Enterprises Ltd.	08/04/2011	E	872	(6,7	)	10% pa	$	0.034	N/A
Eardley Holding A.G.	08/04/2011	E	218	(6,7	)	10% pa	$	0.034	N/A
Round Enterprises Ltd.	11/08/2011	E	400	(7	)	10% pa	$	0.034	1.3787
Eardley Holding A.G.	11/08/2011	E	100	(7	)	10% pa	$	0.034	1.3787
Round Enterprises Ltd.	02/10/2012	E	1,000	(7	)	10% pa	$	0.034	1.3260
Eardley Holding A.G.	02/14/2012	E	200	(7	)	10% pa	$	0.034	1.3260
Round Enterprises Ltd.	04/19/2012	E	321	(7	)	10% pa	$	0.034	1.3100
Eardley Holding A.G.	04/19/2012	E	81	(7	)	10% pa	$	0.034	1.3100
Round Enterprises Ltd.	05/04/2012	E	480	(7	)	10% pa	$	0.034	1.3152
Eardley Holding A.G.	05/04/2012	E	120	(7	)	10% pa	$	0.034	1.3152
Round Enterprises Ltd.	09/03/2012	E	200	(7	)	10% pa	$	0.034	1.2576
Eardley Holding A.G.	09/03/2012	E	50	(7	)	10% pa	$	0.034	1.2576
Round Enterprises Ltd.	11/14/2012	E	500	(7	)	10% pa	$	0.034	1.2718
Eardley Holding A.G.	12/06/2012	E	125	(7	)	10% pa	$	0.034	1.3070
Round Enterprises Ltd.	01/16/2013	E	240	(7	)	10% pa	$	0.034	1.3318
Eardley Holding A.G.	01/16/2013	E	60	(7	)	10% pa	$	0.034	1.3318
Round Enterprises Ltd.	03/25/2013	E	400	(7	)	10% pa	$	0.037	1.2915
Eardley Holding A.G.	04/14/2013	E	150	(7	)	10% pa	$	0.034	1.3056
Round Enterprises Ltd.	04/14/2013	E	600	(7	)	10% pa	$	0.034	1.3056
Eardley Holding A.G.	05/15/2013	E	170	(7	)	10% pa	$	0.037	1.2938
Round Enterprises Ltd.	05/15/2013	E	680	(7	)	10% pa	$	0.037	1.2938
Eardley Holding A.G.	06/24/2013	E	60	(7	)	10% pa	$	0.025	1.3340
Round Enterprises Ltd.	06/24/2013	E	240	(7	)	10% pa	$	0.025	1.3340
Eardley Holding A.G.	08/05/2013	E	80	(7	)	10% pa	$	0.018	1.3283
Round Enterprises Ltd.	08/05/2013	E	320	(7	)	10% pa	$	0.018	1.3283
Total Short Term Principal Amounts		E	29,005
Accrued Interest		E	10,118
Total Convertible Notes to Related Parties		E	39,123
Norwood Contingent Liability		E	236	(5	)

TOTAL LOANS, NOTES,AND CONTINGENT LIABILITY		E	39,359

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

(5) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company issued to Norwood Immunology Limited (“NIL”) a convertible redeemable note (the “Note”) in the principal amount of E2,500 with a maturity date of June 30, 2014 and bearing interest at 10% per annum. The note is secured against 1/3rd of Bestewil common stock. On March 28, 2013, Mymetics agreed with Norwood Immunology Ltd (NIL) to amend the terms and conditions of the E2,500 loan that expired on June 30, 2013. Under the terms of the Amendment, Mymetics agreed to make a series of payments as follows to release it from any obligation to share revenues from the sale of Mymetics' intranasal influenza vaccine, RSV vaccine and HSV vaccine: (i) by April 30, 2013 E521 consisting of E500 of principal under the Loan Note and E21 of accrued interest for the month of April 2013 on the outstanding principal balance of E2,500, (ii) by May 31, 2013 E517 consisting of E500 of principal under the Loan Note and E17 of accrued interest for the month of May 2013 on the outstanding principal balance of E2,000, (iii) by September 30, 2013 accrued interest of E51 on the outstanding principal balance of E1,500 under the Loan Note and (iv) by June 30, 2014 E1,576 consisting of E1,500 to extinguish the outstanding principal balance of the Loan Note and E76 to extinguish the remaining unpaid accrued interest owed on the outstanding principal balance of the Loan Note. Upon payment by Mymetics of E500 of the principal under the Loan Note, the number of shares of Bestewil Holding B.V. pledged by Mymetics is reduced from 33% (6,290 shares) to 26.7% (5,032 shares). Upon payment by Mymetics of E1,000 of principal under the Loan Note the number of shares of Bestewil Holding B.V. pledged by Mymetics is reduced from 33% (6,290 shares) to 20% (3,774 shares). In addition, Mymetics shall issue, within twenty days of receipt of the first tranche of the investment but no later than March 31, 2014, US$325 in shares of the Company’s common stock at the lower of (i) the average closing price of the last two months prior to the repayment date or (ii) the lowest conversion price for any Mymetics shareholder loan that has been converted two months prior or two months after such repayment or (iii) Investor Price.